Advanced Cell Technology (ACTC) Reports Milestone Achievement in Phase I/II Embryonic Stem Cell Clinical Trials
Investigators in Advanced Cell Technology’s phase I/II clinical trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) report that they have observed evidence of engraftment of the transplanted human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as well as visual acuity gain in patients treated throughout the trial’s duration. The company has reached the halfway point in all three of its ongoing trials, stopping to assess the data and activity of the transplanted RPE cells. These most recent findings mark the first time the company has achieved engraftment and persistence in AMD, and is…